Scancell Share Discussion Threads

[drdobson1] 27/2/2018 09:02

Strange when the idiot is quiet the Share price rises but when he sticks his head out the bunker it goes down.
Is there a correlation.Perhaps if he stays quiet it might go back up.

[terror] 27/2/2018 08:36

There's nothing like a collapse in the share price to silence the MFF.

[the real lozan] 26/2/2018 16:41

Rumour has it - that HE is trying to build HIMSELF....A PERSONALITY

[tosh 123] 26/2/2018 16:35

I wouldn't let that idiot pour me a cup of tea let alone pour any concrete.
Notice how his £6 in 6 months timescale has suddenly altered AGAIN as well... He's an utter fraud, and a clown.
He's been quoting £6 for years, the plank.

The only concrete that really needs pouring is to fill the void between his ears, and don't be fooled, to fill that cavity will take quite a few cube.

[the real lozan] 26/2/2018 15:34

Lovin it Kev, Lovin it -
inanaco
Today 15:10
"Doing a Construction project however -2c has stalled the use of cement hence i might post a bit"
.
Bit of a reverse action then... as
HE has been *Doing a DEMOLITION job* on HIS victims bank accounts = For YEARS

[tosh 123] 26/2/2018 12:10

Looks like a little bit of profit taking from those who bought in at the 10p range, and I don't blame them, a 50% increase in a few months is not to be sniffed at.
This will probably take a breather for a couple of days before another steady increase, unless of course theres another RNS giving details on funding, or the lack of it, in which case, all bets are off, either way.

[the real lozan] 26/2/2018 09:11

The 'current' S P -
I don't think there CAN be anyone who is not pleased to see the S P = Where it is NOW, rather than where it was at the start of this month.
However, IF one 'looks at the WIDER picture' / 'CASH Balance sheet'... One might form a diverse view from the 'tunnel vision' trHYPE gang.
Bearing in mind, that SCLP does NOT have an 'income' ATM... BUT... DOES have "to keep the lights on" ---- IF, One looks at the calander, Balance sheet, "Current S P", a REALIST might deduce, that a 'PLACING' in the "Current S P range"... could be a WISE move for SCLP BoD.
In fact, this may be seen as "SET-UP" for just that.
Given that in 6 months time, FUNDS will be 'a more PRESSING matter'
.
One would be UNWISE to believe that SCLP BoD... will not be 'thinking about it'
.
Of course, *WE ALL* know ... The trHYPE gang DON'T WANT to 'think about it'
OR
What it might MEAN to their 'STILL underwater holdings' ???

[drdobson1] 24/2/2018 15:51

Am sure we will all enjoy the rise.
I am only a disciple of Herbalife and no one else BUT do approve of the informed and respectful way that LOZ,TOSH and others put forward a balanced view.
They have always stayted that the science is good BUT until the FUNDING issue is sortted the Market will not be CONvinced.
Every time there is a rise the trYPERS get EXcitted £6 ASHARE.All the Astute are saying us be cautious.
It IS the blatant LYING by some of the CON merchants to MISLEED people that is the biggest problem here NOT the ASTUTE who are usually proved to be right
But no matter can afford to GIVE the KIDS a bit more pocket money this month even without the Herbalife Bonus UNLESS this rise is just hot air befireva placing

[gooosed] 24/2/2018 14:53

Calculus Investor Forum recording ?

[the real lozan] 24/2/2018 10:36

Is that 'fried' or 'boiled' rise ???

[fragma] 24/2/2018 07:20

Anyway, enjoy the rise.

[drdobson1] 23/2/2018 23:42

Fragma
You are right the ASTUTE bought in at 10p so will be well in PROFIT.
They will also probably sell a few just in case it DOES NOT go up on Monday but goes DOWN due to the FUNDING ELEPHANT in the room which is NOT sorted in the VERY near future and OF COURSE buy back more at a LOWER price.
So IF the Price goes UP or DOWN they gain UNLIKE the TrYYPERS who only gain IF the price goes UP.
iF you look at EVIDENCE of WHO has been proved RIGHT it is the ASTUTE who are the Winners and the thHYPERS who are LOOSERS

[fragma] 23/2/2018 21:48

Don't worry terror, all those shares that the astute loaded up at 10p will go up even more on monday and tuesday and for a while yet.

Bet you cant wait.

Think of all the profit !

[terror] 23/2/2018 16:47

what happened to the 2:30 surge. Seems that the MFF got it all wrong again

[sarkasm] 23/2/2018 12:57

Big pharma could turn to viruses to boost cancer immunotherapies

Big pharma could turn to viruses to boost cancer immunotherapies
Richard Staines Richard Staines
February 23, 2018

Merck & Co’s $394 million acquisition of Viralytics has stoked interest in oncolytic viruses, a class of drugs that have been in the shadow of the checkpoint inhibitors and CAR-T therapies that are helping to set the standard of care in cancer.

But Merck’s deal to acquire Viralytics suggests this could be about to change, according to one of the Australian company’s close competitors, Norway’s Targovax.

Representatives of Targovax interviewed by pharmaphorum said the marketplace is set to get increasingly crowded in the future as pharma tries to use the approach to improve efficacy of checkpoint inhibitors.

There is only one FDA-approved oncolytic virus, Amgen’s Imlygic (talimogene laherparepvec) in 2015, but sales have been disappointing.

But with another 10 oncolytic viruses in clinical development, and another 40 in labs, the hope is that oncolytic viruses could be used to ‘prime’ tumours before treatment with checkpoint inhibitor immunotherapy, which has a response rate as low as 20% in some cancers.

Oncolytic viruses work by injecting genetic material into cancer cells, which modify them and make them visible to the immune system, which moves in to destroy the.

The issue with Imlygic is that it is approved as a monotherapy – and the thinking is that oncolytic viruses are likely to be more effective when used in combination with other drugs, notably immunotherapy drugs such as checkpoint inhibitors.

This is the approach taken by Viralytics, and by Targovax, which is looking to find partners as it progresses its two oncolytic viruses through the clinical trial process.

Now that Viralytics is effectively part of Merck & Co, this leaves Targovax as one of the most advanced independent biotechs working with oncolytic viruses.

Bristol-Myers Squibb has also done a big oncolytic virus deal, acquiring rights late last year to an “armed virus” targeting cancer from the UK biotech, PsiOxus Therapeutics, worth almost $900 million if the project is successful.

Merck deal ‘no suprise’

Targovax’s chief medical officer, Magnus Jaderberg, told pharmaphorum in an interview that the Viralytics deal came as no surprise following strong phase 2 results from its Cavatak, based on the Coxsackievirus, back in 2015.

Magnus Jaderberg

Jaderberg said: “As soon as they released the data we felt that somebody would go after them and we were right. We were not surprised about the deal and we think it is very positive for us.”

He expects more interest in oncolytic viruses from Roche and Genentech, which so far have not done a big oncolytic virus deal, perhaps to boost their immunotherapy Tecentriq, which has produced some mixed results in trials.

Already partnered with Medimmune on one deal, Targovax is planning a phase 2 trial of its adenovirus-based drug TG01, targeting resected pancreatic cancer in combination with Merck’s Keytruda (pembrolizumab).

This could be extended to a phase 3 trial leading to registration in this disease, where there has been no significant progress for the best part of two decades CHECK.

Targeting RAS mutations, the drug could be used in 30% of all cancers that express this biomarker, suggesting a sales potential well in excess of the $400 million a year the company forecasts if approved in early pancreatic cancer.

Also in the Targovax pipeline is ONCOS-102, an oncolytic virus, which is in phase 1b/2 trials for mesothelioma and could produce an early readout in the coming weeks.

It is also developing ONCOS-102 in partnership with AstraZeneca’s MedImmune unit and the Cancer Research Institute for ovarian and colorectal cancer.

Jaderberg has been busy tapping up his contacts in big pharma having previously worked as chief medical officer for Bristol Myers Squibb in Europe.

He has already been in talks with manufacturers of checkpoint inhibitors to try and get licensing deals in place to fund further development.

Wiklund said: “It is tough as a small biotech to lift a phase 3 programme – it is obvious we are interested in licensing out one or both of our programmes.”

But Targovax’s CFO Erik Digman Wiklund was cagey about the prospects of a big buyout as seen in the case of Viralytics. “It is incredibly unpredictable, it is difficult to make any comment,” he said.

[miavoce] 23/2/2018 11:53

Placings certainly do happen when a company's share price has risen off the back of good news. In these cases it is win win - ii's get volume shares without having to go into the market (in which case they would have to pay more), and the company gets cash at or around the prevailing share price (maybe even a premium if the news driving the price presages further share price increase).

Whether SCLP will undertake a placing to take advantage of the improved price remains to be seen (IMO I expect not - I believe funding will come from another route), but I don't believe that SCLP's share price is being / can be artificially driven up to enable a higher priced placing.

[the real lozan] 23/2/2018 11:21

Smiler -
Hope you 'hit-your-target'... BUT... Will you stick with your 'plan' ...or be tempted to 'stray-from-you-plan' and RISK +++ ???
Remember folks -
N B = The 'elephant is STILL in the room'...{ ANY money presaged by RG = WILL come at a COST}
And - A 'placing' may STILL be "On the CARDS" ..especially, with a more CONvenient S P
Some might think this is *Set-up* for just such a 'move' ???

[miavoce] 23/2/2018 11:14

How is it being pushed up red army ? Normally before a raise the price tends to fall - see it lots of times.

[red army] 23/2/2018 11:12

I get the feeling that this is being pushed up for a cash raise anytime soon. 15p at the moment but was hoping for a rise to 22p to get a 20p raise.

[gazza] 23/2/2018 11:11

Terror, the REAL astute were accumulating shares at 10p rather than slagging off the CEO.

[miavoce] 23/2/2018 11:07

Surely something brewing. Maybe we are about the see the arrival of the money presaged by RG.

[terror] 23/2/2018 11:04

70% rise since Goodfellow was ousted.

The ASTUTE knew who was the weakest link

[terror] 23/2/2018 10:04

Is it £1 yet with this TrHYPE we see on the MFF, or is it still 30p below their buy in price?